KOD

Kodiak SciencesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$70.00

Analysis reference price unavailable

Analysis 2026-03-27 · RankAlpha Sentiment AI

Most likely

Base case

50%

Probability

Target price

$42.00

Analysis reference price unavailable

Analysis 2026-03-27 · RankAlpha Sentiment AI

B-

Bear case

30%

Probability

Target price

$18.00

Analysis reference price unavailable

Analysis 2026-03-27 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-03-27

AI commentary

Market sentiment turned strongly positive after the March 26-27 positive topline announcement; news flow and 8-K/IR updates are now the dominant drivers of price moves [#8-K-2026-03-27] [#IR-undated]. Analysts' consensus targets remain dispersed, leaving room for re-rating if management provides a clear submission timeline [#SERP-1].

RankAlpha Sentiment AI - 2026-03-27

Open full AI memo

Evidence flagged

high-coverage report lacks a dated company-specific catalyst beyond generic cadence

Impact

tentative

Confidence

AI events

2026-03-26eventPositive topline announced from GLOW2 Phase 3 (market-moving press release / 8-K)High impact

Kodiak announced positive topline results for the GLOW2 second Phase 3 study in diabetic retinopathy on March 26-27, 2026 (company press release / 8-K) — immediate commercial/regulatory implications to be disclosed in follow-up filings [#8-K-2026-03-27] [#IR-undated].

2026-06-25catalystUpcoming quarterly / investor update to quantify commercial readiness and cash runwayHigh impact

Next quarterly results / investor update should disclose updated cash runway and commercial preparations tied to the GLOW program; use the company's 10-Q / IR schedule to monitor [#10-Q-2025-11-13] [#10-K-2025-03-27].

2027-03-27catalystRegulatory pathway and potential filing (NDA/BLA) decision following GLOW2 toplineHigh impact

Management is expected to outline next regulatory steps (e.g., planned submission timing or End-of-Phase-2/3 meeting) after the GLOW2 topline; monitoring planned 8-K/IR updates and upcoming investor communications for a formal submission timeline [#8-K-2026-03-27] [#IR-undated].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-03-27 • Updated nightlySource: Internal modelMethodology